Zero concentrations – all samples – full replicate [RSABE / ABEL]

posted by luvblooms  – India, 2014-04-07 13:50 (4055 d 04:59 ago) – Posting: # 12784
Views: 13,591

Dear Pash


❝ We have thought about all possibilities as mentioned above, but there is no evidence for noncompliance in the study.


❝ However the formulation (Mesalamine DR tablet) itself has such property. please refer Literature Reference.



I too am talking about the Meslamine DR tablet formulations and my experience with it. And what I told you were from those learning only. You need to control your clinical part and design your study appropriately and belive me this value will decrease to a level of 10-15% from 45-50%.


❝ Our main concern is how to handle such incomplete data statistically in scaled average (full/partial replicate) design study :confused::confused:


IMHO, if your only concern is the data handling and stats, best option is to go for Controlled corresponence with FDA.

~A happy Soul~

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
147 visitors (0 registered, 147 guests [including 8 identified bots]).
Forum time: 18:50 CEST (Europe/Vienna)

Only dead fish go with the current.    Scuba divers' proverb

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5